Ivacaftor is a potent and selective potentiator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that targets F508del-CFTR and G551D-CFTR (EC50 values are 25 nM and 100 nM, respectively); its potentiation activity depends on the level of CFTR phosphorylation. Ivacaftor reversibly binds to wild type (WT-CFTR) and G551D-CFTR mutants, increasing the open probability via an ATP-independent mechanism, and enhances cAMP/PKA-signaling mediated gating activity for both WT-CFTR and G551D-CFTR mutants. In cultured human CF bronchial epithelia with G551D/F508del mutations, Ivacaftor increases Forskolin (Cat. No. 1099)-induced transepithelial current (EC50 = 236 nM) and increases chloride secretion by 10-fold. Also rescues endothelial CFTR expression and function and prevents endothelial barrier failure and protein leak in human pulmonary microvascular endothelial cells. Ivacaftor is orally bioavailable.
Caractéristiques techniques
| Marque | Tocris Bioscience |
| Réf. B-LABO | BL-RE-160861 |
| Réf. fabricant | 30000424 |
| Nom chimique ou matériau | N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide |
|---|
| CAS | 873054-44-5 |
|---|
| Quantité | 50 mg |
|---|
| Cible | CFTR |
|---|
| Formule moléculaire | C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub> |
|---|
| Pureté | 98% |
Une question, une configuration particulière ?
Contactez-nous pour un devis.